You are here: Industry Insights > Market News > Canvas paints a mixed picture for J&J’s Invokana

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

β-Nicotinamide adenine dinucleotide phosphate

Canvas paints a mixed picture for J&J’s Invokana

epvantageJune 13, 2017

Tag: Canvas

Favorites

The cardiovascular benefit with the SGLT2 inhibitors looks like a class effect. The latest to succeed is Johnson & Johnson’s Invokana, which met its primary endpoint in an analysis of the Canvas and Canvas-R cardiovascular outcomes trials presented today at the American Diabetes Association meeting.

The 14% cardiovascular benefit seen with Invokana mirrors that observed with Lilly and Boehringer’s Jardiance in the Empa-Reg Outcome trial. But an increased risk of amputation could see Invokana lose market share to the other SGLT2s, particularly Jardiance, which already has a cardiovascular outcomes benefit on its label.

Previous:Xencor Appoints Biology VP

Next:Veloxis Pharmaceuticals A/S announces agreement

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

Canvas paints a mixed picture for J&J’s Invokana | Pharmasources.com

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

MetP Pharma AG today announced tirzepatide in a BrainDos™ formulation reduced pro-inflammatory cytokine Il-6 by more than 80% and 2-fold stronger than with aqueous tirzepatide solution.

Canvas paints a mixed picture for J&J’s Invokana

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may like
More>>

Canvas paints a mixed picture for J&J’s Invokana

Related News

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

You may likeMore>>

You may like
More>>